Actively Recruiting
Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury
Led by The Second Hospital of Anhui Medical University · Updated on 2025-12-17
166
Participants Needed
3
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to investigate whether morphine modulates the functions of the stellate ganglion to reduce myocardial ischemia/reperfusion injury in AMI patients. It will also assess the safety of injecting morphine around the stellate ganglion via ultrasound guidance. The main questions it aims to answer are: 1. Does morphine regulate stellate ganglion function to reduce myocardial ischemia/reperfusion injury in AMI patients? 2. What medical problems do participants experience when receiving injected morphine around the stellate ganglion? Researchers will compare morphine to a placebo saline (as a control group) to determine whether stellate ganglion infiltration with morphine effectively treats patients with AMI following primary PCI. Participants will: * Receive a single injection of morphine or saline around the stellate ganglion. * Evaluate the percentage of infarct size 7 days after surgery, or at discharge if the duration is shorter than 7 days. * Record their symptoms and any major adverse cardiovascular and cerebrovascular events within 30 days post-surgery.
CONDITIONS
Official Title
Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older, male or female
- Diagnosed with acute ST-segment elevation myocardial infarction (STEMI) planned for percutaneous coronary intervention (PCI)
- STEMI defined by ECG showing ST-segment elevation of at least 0.2 mV in two or more adjacent leads or new left bundle branch block
- Within 24 hours of onset of infarct-related chest pain
- Informed consent obtained from patient and family
You will not qualify if you...
- Severe complications of myocardial infarction such as uncontrollable acute left heart failure, pulmonary edema, severe cardiogenic shock after CPR, or severe mechanical complications (ventricular septal defect, papillary muscle rupture, left ventricular free wall rupture)
- History of old myocardial infarction, cardiomyopathy, or malignant arrhythmias controlled by antiarrhythmic drugs
- Coagulation disorders from systemic diseases or current use of anticoagulants making injection unsuitable
- Allergy to opioids or history of opioid addiction
- Participation in other clinical studies
- Pregnant or breastfeeding women
- Severe organ dysfunction or failure including liver, renal, or respiratory failure
- Severe infections
- Severe mental illness preventing cooperation or use of antipsychotic drugs
- Other conditions deemed unsuitable by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230022
Actively Recruiting
2
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230032
Actively Recruiting
3
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China, 410011
Actively Recruiting
Research Team
S
Shiyun Jin, M.D., PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here